IDO1 and pachyonychia congenita: Both clinical and preclinical studies support this mechanism: interferon-α administration induces IDO1 and depressive symptoms [34]; in orthotopic PC mouse models, IDO1 inhibition reduces KYN levels and depressive-like behaviors, whereas an SSRI produces no improvement [35].